New Review of PARADIGM-HF Results: LCZ696, an Angiotensin-neprilysin Inhibitor, Versus Enalapril in Heart Failure

Thursday, June 9, 2016 Heart Disease News J E 4

LONDON, June 9, 2016 /PRNewswire/ --

José Silva Cardoso. European Journal of Arrhythmia & Electrophysiology, 2016;2(1):14-7.

     (Logo: )

Published recently in European Journal of Arrhythmia & Electrophysiology, the peer-reviewed journal from touchCARDIO, José Silva Cardoso discusses the important findings from the PARADIGM-HF study. This study indicated that the angiotensin receptorneprilysin inhibitor, LCZ696, is superior to enalapril in reducing the risks of cardiovascular death and of hospitalisation for heart failure in patients with heart failure and reduced ejection fraction.

The full peer-reviewed, open-access article is available here:

Disclosure: José Silva Cardoso has consulted and received speaker fees and investigational grants from Novartis. He was the National Coordinator of PARADIGM-HF for Portugal. This article is a short opinion piece and has not been submitted to external peer reviewers, but was reviewed by the Editorial Board before publication.


touchCARDIO (a division of Touch Medical Media) publishesEuropean Journal of Arrhythmia & Electrophysiologyy, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of cardiology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

For inquires please contact: Nicola Cartridge - Managing Editor Providing practical opinion to support best practice for busy healthcare professionals.




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Mercola Celebrates Father's Day by Helping Dads St...
A New Review Stresses that Non-Vitamin K Antagonis...